ArticleBioMed research international2018
Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx: A Clinical Retrospective Study of 13 Cases.
Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Inflammatory Myofibroblastic Tumour of Head and Neck: A Systematic Review Plus Meta-Analysis.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Pooled it
- Case Report: Inflammatory myofibroblastoma of the right forearm in an adult male: a clinical report.Frontiers in oncology · 2026Article
- Case Report: Dose-escalated volumetric modulated arc therapy achieving bowel and renal protection for large retroperitoneal inflammatory myofibroblastic tumor invading ureter and inferior vena cava.Frontiers in oncology · 2026Article
- Inflammatory Myofibroblastic Tumor of Maxilla; A Rare Entity to Encounter: from Resection to Rehabilitation-A Case Report with Review of Literature.Journal of maxillofacial and oral surgery · 2025Article
- ALK-negative retroperitoneal inflammatory myofibroblastic tumor treated conservatively: case report.Journal of surgical case reports · 2025Article
- Inflammatory Myofibroblastic Tumor: An Updated Review.Cancers · 2025Review
- Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor.Thoracic cancer · 2025Review
- Clinicopathological and Molecular Features of Primary Inflammatory Myofibroblastic Tumor in Nasal Cavity and Paranasal Sinuses.Pharmacogenomics and personalized medicine · 2025Article
- Article
- Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.Oncology research · 2024Review
- Update of Diagnosis and Targeted Therapy for ALKCurrent treatment options in oncology · 2023Review
- Inflammatory Myofibroblastic Tumor: Two Cases in Head and Neck Region.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Inflammatory Myofibroblastic Tumour: State of the Art.Cancers · 2022Review
- Algorithmic Approach to Fibroinflammatory Sinonasal Tract Lesions.Head and neck pathology · 2021Article
- Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case.Journal of the Egyptian National Cancer Institute · 2020Article
- New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory myofibroblastic tumor (IMT), as a mesenchymal tumor, is common in the lung and abdomen but rare in the paranasal sinus and nasopharynx.
objectiveThis study aimed to summarize the clinical characteristics of IMT in the paranasal sinus and nasopharynx and analyze the relationship between the treatment and the overall survival (OS).
methodThe clinical features, treatment, and follow-up data of patients diagnosed with IMT of the paranasal sinus or nasopharynx from 2006 to 2017 were retrospectively analyzed, and the previous literature was reviewed.
resultsIMT often presents as an ill-defined soft-tissue mass with bone destruction and invasion of surrounding structures. The treatment methods used in this study were different combinations of surgery, prednisone, radiotherapy, and chemotherapy or observation alone. Three of the 13 patients were lost and the follow-up time of the remaining 10 cases ranged from 2 to 87 months (median, 39 months). Two patients died of the disease; the other eight patients were stable. The 5-year survival rate was 72%. Among the four methods of treatment, only treatment with prednisone was significantly correlated with better OS (
conclusionsIMT is an intermediate tumor that often mimics malignancy. We are not sure if IMTs in the nasal cavity are more aggressive because of the biology or if the location and local therapy in the head region is more complicated. Radiologic findings help know the extent of the lesion. For unresectable nasal IMT, combined therapy with glucocorticoids, chemotherapy, and radiotherapy is sometimes a better choice. Glucocorticoids are especially recommended as a basic part of the integrated therapy. However, the standard treatment needs further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.